These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22157043)

  • 21. [Entry inhibitors. Ring-free for a new principle of action].
    Rümmelein N; Jäger H
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():16-20. PubMed ID: 15011578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone uptake studies in rabbits before and after high-dose treatment with 153Sm-EDTMP or 186Re-HEDP.
    Brenner W; Kampen WU; Brümmer C; von Forstner C; Zuhayra M; Czech N; Muhle C; Henze E
    J Nucl Med; 2003 Feb; 44(2):247-51. PubMed ID: 12571217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gamut: soft tissue uptake of bone radiopharmaceuticals.
    Tuncel M; Erbas B; Mahmoudian B
    Semin Nucl Med; 2003 Oct; 33(4):334-7. PubMed ID: 14625845
    [No Abstract]   [Full Text] [Related]  

  • 24. Transient neuropathy after needle-free injection outside of recommended sites.
    Harris M; Larsen G; Valyi M; Walker E; Montaner JS
    AIDS; 2006 Mar; 20(5):784-5. PubMed ID: 16514315
    [No Abstract]   [Full Text] [Related]  

  • 25. Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector).
    Harris M; Joy R; Larsen G; Valyi M; Walker E; Frick LW; Palmatier RM; Wring SA; Montaner JS
    AIDS; 2006 Mar; 20(5):719-23. PubMed ID: 16514302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient acceptance of self-injected enfuvirtide at 8 and 24 weeks.
    Cohen C; Hellinger J; Johnson M; Staszewski S; Wintfeld N; Patel K; Green J
    HIV Clin Trials; 2003; 4(5):347-57. PubMed ID: 14583851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Enfuvirtide].
    Gerstoft J
    Ugeskr Laeger; 2004 Nov; 166(48):4355-7. PubMed ID: 15587625
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients.
    Wiznia A; Church J; Emmanuel P; Eppes S; Rowell L; Evans C; Bertasso A;
    Pediatr Infect Dis J; 2007 Sep; 26(9):799-805. PubMed ID: 17721374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients.
    Lalezari JP; Patel IH; Zhang X; Dorr A; Hawker N; Siddique Z; Kolis SJ; Kinchelow T
    J Clin Virol; 2003 Oct; 28(2):217-22. PubMed ID: 12957192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Combined treatment with fusion inhibitor. HIV-1 viruses under control longer].
    MMW Fortschr Med; 2004 Apr; 146(15):68. PubMed ID: 15373030
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration.
    True AL; Chiu YY; Demasi RA; Stout R; Patel I
    Pharmacotherapy; 2006 Dec; 26(12):1679-86. PubMed ID: 17125431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initiation of therapy with a subcutaneously administered antiretroviral in treatment-experienced HIV-infected patients: understanding physician and patient perspectives.
    Horne R; Cooper V; Fisher M
    AIDS Care; 2008 Oct; 20(9):1029-38. PubMed ID: 18825512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Darunavir offers potent new combo when used with enfuvirtide in ritonavir-boosted regimen.
    Edmunds-Ogbuokiri T
    HIV Clin; 2007; 19(1):1-3. PubMed ID: 17405221
    [No Abstract]   [Full Text] [Related]  

  • 34. Impact of education and support on the tolerability and quality of life in a cohort of HIV-1 infected patients treated with enfuvirtide (SURCOUF Study).
    Allavena C; Prazuck T; Reliquet V; Verdon R; Perré P; Le Moal G; Billaud E; Raffi F
    J Int Assoc Physicians AIDS Care (Chic); 2008; 7(4):187-92. PubMed ID: 18599881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Enfuvirtide in HIV patients: a nursing guideline for medication management].
    Bigler S; Nicca D; Spirig R;
    Pflege; 2009 Feb; 22(1):29-38. PubMed ID: 19173176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lung, gastric, and soft tissue uptake of Tc-99m MDP and Ga-67 citrate associated with hypercalcemia.
    Castaigne C; Martin P; Blocklet D
    Clin Nucl Med; 2003 Jun; 28(6):467-71. PubMed ID: 12911094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is (99m)Tc-labelled pamidronate a better agent than (99m)Tc-medronate for bone imaging?
    Kumar V; Kumar D; Howman-Giles RB; Little DG
    Nucl Med Commun; 2007 Feb; 28(2):101-7. PubMed ID: 17198350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks.
    Sayana S; Prosser P; Ricaurte JC; Sanchez S; Hamwi G; Hershey-Weber J; Chien C; Easley A; Nguyen T; Wilson L; Khanlou H
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(2):85-6. PubMed ID: 19369697
    [No Abstract]   [Full Text] [Related]  

  • 39. Unusual extraosseous tumoral accumulation of 99mTc-MDP in non-Hodgkin's lymphoma in two cases.
    Ceylan Gunay E; Erdogan A; Apaydin D
    Rev Esp Med Nucl; 2011; 30(3):162-4. PubMed ID: 20580467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.
    Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M
    Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.